Estimation of direct cost of managing rheumatoid arthritis treatment to Pakistani patients using real‐world follow‐up data

• Published in: International journal of rheumatic diseases 2020-03, Vol.23 (3), p.325-333
• Main Authors: Naqvi, Atta Abbas, Hassali, Mohamed Azmi, Naqvi, Syed Baqir Shyum, Kachela, Bharti, Khan, Irfanullah
• Format: Article
• Language: English
• Subjects: Adult; Antirheumatic Agents - economics; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - diagnosis; Arthritis, Rheumatoid - drug therapy; Arthritis, Rheumatoid - economics; Arthritis, Rheumatoid - epidemiology; cost analyses; Cost-Benefit Analysis; Costs; Databases, Factual; direct cost; Drug Costs; Female; health care economics; health expenditure; Health Expenditures; Hospitals; Humans; Laboratories; Male; Medical equipment; Middle Aged; Pakistan - epidemiology; Patients; Physical therapy; Prospective Studies; Rheumatoid arthritis; Time Factors; Treatment Outcome
• ISSN: 1756-1841; 1756-185X
• DOI: 10.1111/1756-185X.13776

Objective This study aimed to estimate annual direct cost attributed to rheumatoid arthritis (RA) treatment from a patient's perspective using real‐world patient follow‐up data from hospitals’ electronic database. Methods A prospective 1‐year study was conducted in rheumatology clinics of tertiary care hospitals of Karachi, Pakistan. Cost‐of‐illness methodology was used and all patient data related to costs of rheumatologist visits, physical therapy sessions, medications, assistive devices and laboratory investigations were obtained directly in printed hardcopies from patient electronic databases using their medical record numbers. Transportation cost was calculated from patient‐reported log books. Data were analyzed through IBM SPSS version 23. Patients were asked to sign a written consent and the study was ethically approved. Results The mean age of patients (N = 358) was 48 years. Most patients (73.7%) were female, married (86%) and had basic education (71.8%). Average cost of rheumatologist visits was PKR 11 510.61 (USD: 72.05) while it was PKR 66 947.37 (USD: 419.07) for physical therapy sessions. On average, medicines and medical devices costs were estimated at PKR 10 104.23 (USD: 63.25) and PKR 7848.48 (USD: 49.13) respectively. Cost attributed to diagnostic and laboratory charges was PKR 1962.12 (USD: 12.28) and travel expense was PKR 6541 (USD: 40.95). The direct expenditure associated with managing RA was PKR 37 558 (USD: 235.1). All costs were reported per annum. Conclusion Patient with RA in Pakistan pay a considerable amount of their income for managing their condition. Most patients have no provision for insurance which is a need considering the nature of the disease and associated productivity loss that would significantly lower income as the disease progresses.